New therapeutic approach shows promise for pediatric high-grade gliomas
- OPACC
- Mar 18
- 1 min read
Paediatric high-grade gliomas (pHGG) in particular are a mostly fatal disease group with a median survival time of less than 18 months after diagnosis and limited treatment options. A research team from MedUni Vienna/University Hospital Vienna, the Dana-Farber Cancer Institute and the University of Michigan Medical School identified Platelet-Derived Growth Factor Receptor Alpha (PDGFRA) as a promising therapeutic approach.
Recent Posts
See AllThe FDA has granted Rare Pediatric Disease Designation for NEO100 in the treatment of pediatric-type diffuse high-grade gliomas, a type...
Untreated growth hormone deficiency was associated with neurocognitive impairment and reduced physical functioning among adult survivors...
A Phase I clinical trial demonstrated that a targeted approach to treating a deadly brain tumor in children called diffuse intrinsic...
Comments